Insperity Inc Dossier - Source-backed chat

Insperity Inc

NSPNYSE

SectorIndustrials

IndustryStaffing & Employment Services

Beta (adjusted)0.68

Intrinsic Value $86.83median of 3 methodsbased on filings through 30 Jun 2026

Market Price $48.63Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 79% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+79%)

Data confidence Sign in to view data confidence

Market Cap $1.9B

Enterprise Value $1.7B

Shares Outstanding 38M diluted

Next Earnings Date3 Nov 2026

Last ex-dividend4 Jun 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Insperity is executing a critical margin recovery plan in 2026 to overcome severe healthcare benefit cost pressures experienced in 2025. While Q1 2026 financial results demonstrated early success with Adjusted EBITDA and EPS beating consensus estimates, unit growth remains under pressure. Average paid worksite employees (WSEEs) declined by 1% due to deliberate pricing adjustments, strict client selection criteria, and weaker small business hiring sentiment. The launch of HRScale serves as a key product expansion targeting middle-market accounts, but near-term growth is expected to remain flat. Given the balanced risk-reward profile and a consensus rating of 'Reduce' or 'Hold' among Wall Street analysts, a Hold recommendation is warranted until sustainable unit growth momentum is reestablished in 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$38.00

Mean target$51.75

High · most bullish analyst$61.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$38.0015%

Healthcare benefit costs surge again, outpacing the pricing adjustments and contract protections. Client attrition rises above the historical 12% ceiling as small businesses reject higher pricing. Macroeconomic headwinds worsen, leading to severe layoffs among existing clients and a sharp contraction in new client sales, causing FY 2026 Adjusted EPS to fall to the low end of the $1.60 guidance.

Base CaseCentral scenario

$51.7560%

Matches the consensus mean

Insperity successfully stabilizes its gross profit per employee through its updated UnitedHealthcare contract terms and plan design changes. Average paid WSEEs remain flat to slightly down, landing within the guided range of 303,000 to 307,000 for FY 2026. Operating expenses continue to decline (excluding restructuring charges) as HRScale investment costs taper off in the second half of the year, allowing the company to meet its full-year Adjusted EBITDA guidance of $170 million to $230 million.

Bull CaseUpside scenario

$61.0025%

The margin recovery plan accelerates faster than expected, driven by lower-than-anticipated benefit claim trends and successful pricing power. HRScale experiences rapid adoption, exceeding the 6,000 committed WSEEs pipeline and driving high-margin software-enabled revenue. Small business hiring sentiment rebounds strongly, reversing the decline in paid worksite employees and driving double-digit unit growth in 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proven execution of the margin recovery plan, with Q1 2026 gross profit showing significant improvement over Q4 2025.
Strong strategic partnership with Workday and the launch of HRScale, expanding the addressable market to tech-forward middle-market clients.
Robust balance sheet with $330 million available under the credit facility and a strong commitment to shareholder returns, offering an attractive dividend yield.
Insider confidence highlighted by CEO Paul J. Sarvadi's open-market purchase of 233,000 shares in mid-2026.

Key Investment Risks

Persistent volatility in healthcare benefit costs and medical claim trends which can severely impact gross margins.
Near-term unit growth headwinds as pricing adjustments and strict client selection criteria pressure new sales and retention.
Dependence on small and medium-sized business (SMB) economic health, making the company highly sensitive to macroeconomic downturns and hiring freezes.

Thesis Invalidation Triggers

Benefit cost per covered employee rising by more than 8% year-over-year, indicating failure of the margin recovery plan.
Average paid worksite employees falling below 300,000, signaling severe client attrition or a deep SMB recession.
Delays or high churn in the HRScale onboarding pipeline, undermining the long-term technology-led growth narrative.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.